Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

• Published in: Med (New York, N.Y. : Online) Vol. 3; no. 4; pp. 249 - 261.e4
• Main Authors: Miyamoto, Sho, Arashiro, Takeshi, Adachi, Yu, Moriyama, Saya, Kinoshita, Hitomi, Kanno, Takayuki, Saito, Shinji, Katano, Harutaka, Iida, Shun, Ainai, Akira, Kotaki, Ryutaro, Yamada, Souichi, Kuroda, Yudai, Yamamoto, Tsukasa, Ishijima, Keita, Park, Eun-Sil, Inoue, Yusuke, Kaku, Yoshihiro, Tobiume, Minoru, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Tokunaga, Kenzo, Ozono, Seiya, Hemmi, Takuya, Ueno, Akira, Kishida, Noriko, Watanabe, Shinji, Nojima, Kiyoko, Seki, Yohei, Mizukami, Takuo, Hasegawa, Hideki, Ebihara, Hideki, Maeda, Ken, Fukushi, Shuetsu, Takahashi, Yoshimasa, Suzuki, Tadaki
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.04.2022
• Subjects: Antibodies, Viral; BNT162 Vaccine; BNT162b2 mRNA vaccine; breakthrough infection; Clinical and Translational Report; COVID-19; COVID-19 vaccine; COVID-19 Vaccines; Humans; neutralizing antibody; Omicron variant; Postoperative Complications; SARS-CoV-2; Vaccination; BNT162b2 mRNA vaccine; Omicron variant; SARS-CoV-2; breakthrough infection; COVID-19 vaccine; neutralizing antibody; Translation to patients

The immune profile against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given population. To fur...